According to the criteria of the GRADE guideline, there was one high-quality evidence, Dai et al. (44) conducted a meta-analysis and reported that the HE4 level can provide a useful prognostic biomarker (only for DFS) for patients with cancers (987 patients with EC, 211 patients with LC, and 98 patients with OC). This evidence concerns the gene WFDC2 and cancer.